We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MiMedx

News List

MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee biospace
March 29, 2018
MiMedx Group, Inc. today announced that the first patient has been enrolled in the Company's Phase 2B Investigational New Drug (IND) clinical trial
MiMedx Announces the Enrollment of the First Patients in the Phase III Clinical Trial of AmnioFix In biospace
January 18, 2018
MiMedx Announces First Trial Patients Are Randomized Into Phase Three MiMedx's Micronized Amniotic AmnioFix® Injectable Investigational New Drug (IND) Clinical Trial for Treating Achilles Tendonitis.
MiMedx to divest Stability Biologics business to focus on biopharma pharmaceutical-technology
August 23, 2017
MiMedx Group has signed a new definitive agreement with former stockholders of Stability to sell its subsidiary, Stability Biologics, back to the stockholders to focus on biopharma.